Dong-A Socio sheds holding company discount with bold shift to operating model

Dong-A Socio Holdings has announced a shift to an operating holding company structure by absorbing its wholly owned subsidiary Dong-A Pharmaceutical through a merger. The move marks the most sweeping change to the group's governance in 13 years, since it first converted to a holding company structure in 2013.

The decision is a strategic move to overcome the limitations of a pure holding company — one that relied on managing subsidiary stakes and collecting dividends — by directly integrating the group's core consumer healthcare business to boost corporate value and accelerate its push into global markets at the same time.

Dong-A Socio disclosed Thursday that its board had voted to absorb Dong-A Pharmaceutical in a merger. The deal will proceed as a small-scale merger with no new share issuance and is expected to close Oct. 1.

Because no new shares will be issued, the shareholder composition and ownership stakes of Dong-A Socio will remain unchanged after the merger closes.

Industry observers are calling the merger a bold bet on restructuring the group's fundamentals. Dong-A Socio had long operated as a pure holding company, drawing its main revenue from managing subsidiary stakes, trademark royalties and dividends. But as competition intensified across the global pharmaceutical, biotech and healthcare sectors, critics argued that separating cash generation and investment execution into different entities made it difficult to move quickly on large-scale mergers and acquisitions or commit capital to next-generation growth drivers.

The core of the change is the shift to an operating holding company — a structure that retains the holding company's role of overseeing group subsidiaries through equity stakes while also directly running its own manufacturing and commercial operations. Dong-A Socio will absorb Dong-A Pharmaceutical's most valuable business lines, including Bacchus, over-the-counter drugs, healthcare and derma cosmetics, along with the subsidiary's stable cash-generating capacity.

With the holding company controlling a robust cash flow directly, the group expects to move swiftly and decisively when funding new investments in global biotech and healthcare or committing to innovative new drug R&D.

The restructuring is also expected to enhance shareholder value. A persistent problem in the Korean stock market has been the so-called holdco discount, where a holding company's valuation is suppressed when it and its subsidiaries are listed simultaneously or when a subsidiary listing appears likely. By fully merging with Dong-A Pharmaceutical — an unlisted, wholly owned unit — Dong-A Socio has preemptively eliminated any future dual-listing concern and opened the door to having the subsidiary's business value reflected directly in the holding company's share price.

Consolidating decision-making — previously split between the holding company and its subsidiary — into a single board and management team is also expected to sharpen operational efficiency and accountability. The unified governance structure lays the groundwork for the group to respond more nimbly to market shifts.

The combined Dong-A Socio plans to accelerate its overseas expansion by leveraging the strong brand infrastructure Dong-A Pharmaceutical has built. The group aims to diversify its e-commerce channels, enter global retail networks and nurture its proven consumer healthcare brands to reorient a sales structure currently concentrated in Korea toward global markets.

"This merger is a decision to advance the achievements of our holding company conversion and lead the global healthcare market," a Dong-A Socio official said. "We will actively secure new growth drivers on the foundation of integrated capital and infrastructure to enhance shareholder value."